Could Prevention Data Give REGEN-COV Competitive Leg Up?

Could Prevention Data Give REGEN-COV Competitive Leg Up?

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
Regeneron announced data on the monoclonal antibody cocktail REGEN-COV showing long-term protection against COVID-19 • Source: Shutterstock

Data showing Regeneron Pharmaceuticals, Inc./Roche Holding AG’s REGEN-COV (casirivimab/imdevimab) has strong efficacy in preventing COVID-19 with one dose may give the antibody cocktail an advantage on the market for drugs to prevent COVID-19 despite concerns about its long-term market durability due to looming competition from oral therapies.

Regeneron announced new data on 8 November from a 1,683-participant Phase III trial it is running with the National Institute...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip